RFG Advisory’s Kiniksa Pharmaceuticals KNSA Stock Holding History

RFG Advisory’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$770K	Buy	+10,318	New	+$760K	0.01%	693

Other funds holding KNSA

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Penn Capital Management Philadelphia, Pennsylvania $1.37B AUM 42.56% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Linden Thomas Advisory Services Charlotte, North Carolina $1.26B AUM 37.95% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Sowell Financial Services North Little Rock, Arkansas $3.12B AUM 22.73% 1-Year Est. Return

RFG Advisory's KNSA Position: Q3 2026 in Review

RFG Advisory opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q3 2026: 10,318 shares worth $770K. The stake represents 0.01% of the portfolio and ranks #693 among its holdings.

92 funds tracked by Wall St. Rank hold KNSA as of Q3 2026.

RFG Advisory held 10,318 shares of Kiniksa Pharmaceuticals worth $770K as of Q3 2026.
Kiniksa Pharmaceuticals was a new RFG Advisory position in Q3 2026.
Kiniksa Pharmaceuticals made up 0.01% of RFG Advisory's portfolio in Q3 2026, its #693 holding.
92 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2026.

Based on RFG Advisory's 13F filing for Q3 2026, filed 3 Nov 2026.